James Cleary Jr. compensation by year
Cencora Summary Compensation Table · the one fiscal year held| Component | FY2018 |
|---|---|
| Salary | $575,000 |
| Bonus | $0 |
| Stock awards | $1,259,940 |
| Option awards | $540,006 |
| Non-equity incentive | $485,640 |
| Pension and deferred compensation | $0 |
| All other | $246,637 |
| Total | $3,107,223 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cencora, Inc. DEF 14A filed January 24, 2020, accession 0001047469-20-000460, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Cencora, Inc. filed document, accession 0001047469-20-000460. Every figure is read from that document and cited to the page and table it appears in. Filed January 24, 2020.
Equity holdings
unvested awards at FY2018 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 23,217 | $2,141,072 | — |
| PSU | 10,316 | $951,342 | — |
| RSU | 4,643 | $428,177 | — |
| RSU | 3,439 | $317,145 | — |
| RSU | 458 | $42,237 | — |
| Option | 7,040 | — | $99.27 |
| Option | 3,292 | — | $98.24 |
| Option | 28,782 | — | $75.61 |
| Option | 38,136 | — | $77.53 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Cencora, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
62 Form 4 lines since the FY2018 proxy (filed January 24, 2020)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-03-11 | Exercise or conversion | — | 12,623 | $0.00 | 165,766.35 |
| 2026-03-11 | Exercise or conversion derivative | — | 12,623 | $0.00 | 0 |
| 2026-03-11 | Tax withholding | — | 5,409 | $350.30 | 160,357.35 |
| 2025-12-17 | Exercise or conversion | — | 45,154 | $86.09 | 180,095.35 |
| 2025-12-17 | Exercise or conversion derivative | — | 45,154 | $0.00 | 0 |
| 2025-12-17 | Tax withholding | — | 26,952 | $344.14 | 153,143.35 |
| 2025-12-15 | Exercise or conversion | — | 199 | — | 135,140.35 |
| 2025-12-15 | Exercise or conversion derivative | — | 199 | $0.00 | 4,534 |
The 8 most recent of 62 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Cencora’s named executive officers, FY2018
as the company reported each| Named executive officer | Role | FY2018 total |
|---|---|---|
| Steven Collis | Chairman, President and Executive Officer Chief | $11,514,115 |
| Tim Guttman | Executive Vice President and Chief Financial Officer(1) | $4,085,699 |
| John Chou | Executive Vice President and Chief Legal & Business Officer | $3,570,604 |
| Robert Mauch | Executive Vice President and Group President, Pharmaceutical Distribution & Strategic Global | $3,405,637 |
| James Cleary Jr. · this page | Executive Vice President and President, Global Commercialization Services & Animal Health(2) | $3,107,223 |
The full Cencora compensation record
free company briefThis page is one person within Cencora's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Cencora proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cencora's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.